- Home
- BNR vs CNTX Comparison
BNR vs CNTX Comparison
Compare BNR & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNR
- CNTX
- Stock Information
- Founded
- BNR 2014
- CNTX 2015
- Country
- BNR China
- CNTX United States
- Employees
- BNR N/A
- CNTX N/A
- Industry
- BNR Medical Specialities
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- BNR Health Care
- CNTX Health Care
- Exchange
- BNR Nasdaq
- CNTX Nasdaq
- Market Cap
- BNR 72.4M
- CNTX 77.2M
- IPO Year
- BNR 2020
- CNTX 2021
- Fundamental
- Price
- BNR $7.32
- CNTX $0.90
- Analyst Decision
- BNR
- CNTX Strong Buy
- Analyst Count
- BNR 0
- CNTX 5
- Target Price
- BNR N/A
- CNTX $6.70
- AVG Volume (30 Days)
- BNR 5.5K
- CNTX 1.1M
- Earning Date
- BNR 12-03-2024
- CNTX 03-20-2025
- Dividend Yield
- BNR N/A
- CNTX N/A
- EPS Growth
- BNR N/A
- CNTX N/A
- EPS
- BNR N/A
- CNTX N/A
- Revenue
- BNR $72,832,704.00
- CNTX N/A
- Revenue This Year
- BNR $52.90
- CNTX N/A
- Revenue Next Year
- BNR $48.35
- CNTX N/A
- P/E Ratio
- BNR N/A
- CNTX N/A
- Revenue Growth
- BNR N/A
- CNTX N/A
- 52 Week Low
- BNR $2.62
- CNTX $0.90
- 52 Week High
- BNR $9.50
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- BNR 63.72
- CNTX 32.63
- Support Level
- BNR $6.68
- CNTX $0.92
- Resistance Level
- BNR $7.32
- CNTX $1.05
- Average True Range (ATR)
- BNR 0.23
- CNTX 0.12
- MACD
- BNR -0.04
- CNTX 0.00
- Stochastic Oscillator
- BNR 93.63
- CNTX 0.50
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.